Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis

Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis

Background: The androgen receptor pathway inhibitors (ARPI), abiraterone acetate and enzalutamide, are commonly used in first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, early resistance to ARPI treatment occurs frequently. Traditionally, the res...

Full description

Saved in:
Bibliographic Details
Main Authors: Catharina J. P. Op ’t Hoog, Sabien J. E. Bosman, Emmy Boerrigter, Niven Mehra, Inge M. van Oort, Nielka P. van Erp, Wietske Kievit
Format: Article
Language:English
Published: SAGE Publishing 2024-12-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359241305084
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items